The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.
 
Yuan-Yuan Jin
Employment - Bound Therapeutics
Leadership - Bound Therapeutics
Stock and Other Ownership Interests - Bound Therapeutics
Research Funding - Bound Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Thomas Jefferson University (Inst)
 
Vilas Shivaji Desai
Stock and Other Ownership Interests - Bound Therapeutics
Research Funding - Bound Therapeutics (Inst)
 
Miguel M. Castro
Employment - Bio-Synthesis
Leadership - Bio-Synthesis
Stock and Other Ownership Interests - Bio-Synthesis
 
Edith P. Mitchell
Leadership - Corvus Pharmaceuticals
Honoraria - Exelixis; Sanofi
Consulting or Advisory Role - Bristol Myers Squib; Genentech; Merck; Novartis
Speakers' Bureau - Ipsen
Research Funding - Genentech (Inst); sanofi (Inst)
 
Eric Wickstrom
Stock and Other Ownership Interests - Bound Therapeutics
Research Funding - Bound Therapeutics (Inst); KOP Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wickstrom, E., and Jin, Y.-Y. (2022) Compositions and Methods for MYC Messenger RNA Inhibitors. U.S. Patent No. 11,306,312 (Inst); Wickstrom, E., and Jin, Y.-Y. (2023) Compositions and Methods for microRNA 21 Inhibitors. U.S. provisional patent application (Inst); Wickstrom, E., and Thakur, M. L. (2021) Compositions and Methods for Treating Diseases and Disorders. U.S. provisional patent application 205961-0013-P2US (Inst)